Alterity Therapeutics (ATHE) Competitors $4.94 -0.08 (-1.59%) Closing price 08/29/2025 03:59 PM EasternExtended Trading$5.00 +0.05 (+1.11%) As of 08/29/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATHE vs. IMRX, NVCT, ACTU, CRBU, TVGN, CYBN, MCRB, NKTX, KYTX, and BDTXShould you be buying Alterity Therapeutics stock or one of its competitors? The main competitors of Alterity Therapeutics include Immuneering (IMRX), Nuvectis Pharma (NVCT), Actuate Therapeutics (ACTU), Caribou Biosciences (CRBU), Tevogen Bio (TVGN), Cybin (CYBN), Seres Therapeutics (MCRB), Nkarta (NKTX), Kyverna Therapeutics (KYTX), and Black Diamond Therapeutics (BDTX). These companies are all part of the "pharmaceutical products" industry. Alterity Therapeutics vs. Its Competitors Immuneering Nuvectis Pharma Actuate Therapeutics Caribou Biosciences Tevogen Bio Cybin Seres Therapeutics Nkarta Kyverna Therapeutics Black Diamond Therapeutics Alterity Therapeutics (NASDAQ:ATHE) and Immuneering (NASDAQ:IMRX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership, earnings and media sentiment. Which has more volatility & risk, ATHE or IMRX? Alterity Therapeutics has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500. Comparatively, Immuneering has a beta of 0.37, suggesting that its share price is 63% less volatile than the S&P 500. Do institutionals and insiders have more ownership in ATHE or IMRX? 2.1% of Alterity Therapeutics shares are owned by institutional investors. Comparatively, 67.7% of Immuneering shares are owned by institutional investors. 38.8% of Alterity Therapeutics shares are owned by company insiders. Comparatively, 22.9% of Immuneering shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has higher earnings and valuation, ATHE or IMRX? Alterity Therapeutics has higher earnings, but lower revenue than Immuneering. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlterity TherapeuticsN/AN/A-$12.54MN/AN/AImmuneering$320K652.63-$61.04M-$1.89-3.04 Does the media refer more to ATHE or IMRX? In the previous week, Immuneering had 9 more articles in the media than Alterity Therapeutics. MarketBeat recorded 11 mentions for Immuneering and 2 mentions for Alterity Therapeutics. Alterity Therapeutics' average media sentiment score of 0.93 beat Immuneering's score of 0.28 indicating that Alterity Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alterity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immuneering 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate ATHE or IMRX? Alterity Therapeutics presently has a consensus price target of $12.00, indicating a potential upside of 142.91%. Immuneering has a consensus price target of $13.00, indicating a potential upside of 126.09%. Given Alterity Therapeutics' higher possible upside, equities research analysts plainly believe Alterity Therapeutics is more favorable than Immuneering.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alterity Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Immuneering 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60 Is ATHE or IMRX more profitable? Alterity Therapeutics' return on equity of 0.00% beat Immuneering's return on equity.Company Net Margins Return on Equity Return on Assets Alterity TherapeuticsN/A N/A N/A Immuneering N/A -146.28%-117.22% SummaryAlterity Therapeutics beats Immuneering on 7 of the 12 factors compared between the two stocks. Get Alterity Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATHE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATHE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATHE vs. The Competition Export to ExcelMetricAlterity TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$44.53M$3.06B$5.68B$9.86BDividend YieldN/A2.29%3.99%4.02%P/E RatioN/A20.9283.1126.58Price / SalesN/A386.08533.39202.35Price / CashN/A44.0537.7059.65Price / Book4.758.0710.576.59Net Income-$12.54M-$53.98M$3.27B$265.83M7 Day Performance-1.59%-0.86%0.57%0.25%1 Month Performance-4.45%6.22%5.99%3.09%1 Year Performance231.54%7.17%48.91%20.06% Alterity Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATHEAlterity Therapeutics2.5881 of 5 stars$4.94-1.6%$12.00+142.9%+227.2%$44.53MN/A0.0010IMRXImmuneering3.4717 of 5 stars$5.95+21.7%$13.25+122.7%+395.7%$177.60M$320K-3.1560Analyst ForecastHigh Trading VolumeNVCTNuvectis Pharma3.4533 of 5 stars$6.49-5.5%$15.33+136.3%-3.4%$174.89MN/A-5.558ACTUActuate TherapeuticsN/A$7.98-4.5%$20.50+156.9%+3.8%$173.43MN/A0.0010Trending NewsAnalyst ForecastAnalyst RevisionCRBUCaribou Biosciences2.7674 of 5 stars$1.88+1.6%$6.67+254.6%-11.4%$172.28M$9.99M-1.06100TVGNTevogen Bio3.7848 of 5 stars$0.92-1.8%$10.00+987.0%+82.8%$172.20MN/A0.003CYBNCybin2.4662 of 5 stars$7.25+1.4%$85.00+1,072.4%N/A$171.03MN/A-1.6550High Trading VolumeMCRBSeres Therapeutics3.0231 of 5 stars$19.23-1.1%$73.67+283.1%+19.9%$170.19M$126.32M-4.18330News CoverageNKTXNkarta2.0874 of 5 stars$2.20-7.2%$13.60+518.2%-61.5%$168.33MN/A-1.49140KYTXKyverna Therapeutics2.5 of 5 stars$3.81-1.0%$15.60+309.4%-53.7%$166.50MN/A-1.0496News CoverageAnalyst ForecastGap UpBDTXBlack Diamond Therapeutics3.3301 of 5 stars$2.87-1.7%$12.40+332.1%-55.0%$166.25M$70M12.4890Positive News Related Companies and Tools Related Companies IMRX Competitors NVCT Competitors ACTU Competitors CRBU Competitors TVGN Competitors CYBN Competitors MCRB Competitors NKTX Competitors KYTX Competitors BDTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATHE) was last updated on 8/30/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alterity Therapeutics Limited - Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Alterity Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
